Global Microbiome Partnering 2012-2018The Global Microbiome Partnering Terms and Agreements 2010 to 2018 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Microbiome Partnering Terms and Agreements report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Microbiome agreements announced in the healthcare sectors, covering:

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual Microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active Microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Microbiome dealmaking with a brief summary followed by a comprehensive listing of Microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific Microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Microbiome partnering company A-Z, deal type definitions and Microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Microbiome partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Microbiome technologies and products.

Report scope

Global Microbiome Partnering Terms and Agreements 2010 to 2018 is intended to provide the reader with an in-depth understanding and access to Microbiome trends and structure of deals entered into by leading companies worldwide.

Trends in Microbiome dealmaking in the biopharma industry since 2010Analysis of Microbiome deal structureAccess to headline, upfront, milestone and royalty dataCase studies of real-life Microbiome dealsAccess to over 200 Microbiome deal records and contract documents where availableThe leading antibody deals by value since 2010Most active Microbiome dealmakers since 2010The leading Microbiome partnering resources

In Global Microbiome Partnering Terms and Agreements 2010 to 2018, the available contracts are listed by:

Company A-ZHeadline valueStage of development at signingDeal component typeSpecific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Executive Summary

Introduction

Trends in Microbiome dealmaking

Introduction

Microbiome partnering over the years

Most active Microbiome dealmakers

Microbiome partnering by deal type

Microbiome partnering by therapy area

Deal terms for Microbiome partnering

Microbiome partnering headline values

Table Microbiome deals with a headline value

Microbiome deal upfront payments

Table Microbiome deals with an upfront value

Microbiome deal milestone payments

Table Microbiome deals with a milestone value

Microbiome royalty rates

Leading Microbiome deals

Introduction

Top Microbiome deals by value

Table Top Microbiome deals by value since 2010

Most active Microbiome dealmakers

Introduction

Most active Microbiome dealmakers

Most active Microbiome partnering company profiles

Enterome Bioscience

Seres Therapeutics

Second Genome

Vedanta Biosciences

Ferring Pharmaceuticals

Mayo Clinic

Diversigen

Johnson & Johnson Innovation

Bristol-Myers Squibb

Janssen Research & Development

Johnson & Johnson Consumer Companies

National Institutes of Health

Zymo Research

American Type Culture Collection (ATCC)

Bertin Pharma

CoreBiome

Crohn's and Colitis Foundation of America

DayTwo

Evelo Biosciences

Finch Therapeutics

Harvard University

Human Longevity

Janssen Biotech

Janssen Human Microbiome Institute

J Craig Venter Institute

Microbiome contracts dealmaking directory

Introduction

Microbiome contracts dealmaking directory

Microbiome dealmaking by technology type

Microbiome

Partnering resource center

Online partnering

Partnering events

Appendices

Microbiome deals by company A-Z

4D Pharma

Abbvie

AIDS Clinical Trials Group

Alimentary Health

Allergan

Amag Pharmaceuticals

American Type Culture Collection (ATCC)

Ariana Pharma

Assembly Biosciences

Azitra

Baylor Miraca Genetics Laboratories

Bertin Pharma

Bill and Melinda Gates Foundation

Biocodex Microbiota Foundation

Biocore

Biofortis

Biomecite Diagnostics

Biomillenia

Biosortia Pharmaceuticals

Boston University School of Medicine

Bristol-Myers Squibb

Cedars-Sinai Medical Center

Centers for Disease Control and Prevention

Centre Leon Berard

Centre National de la Recherche Scientifique

Clalit Health Services

Commense

Companion PBx

CoreBiome

CosmosID

Crohn's and Colitis Foundation of America

CryoXtract

DayTwo

Dermala

Diversigen

DuPont Pioneer

Emulate

EnBiotix

Enterome Bioscience

EpiBiome

Evelo Biosciences

Evogene

Evolve BioSystems

Evotec

ExeGi Pharma

Ferring Pharmaceuticals

Finch Therapeutics

Forsyth Institute

French National Institute for Agricultural Research

Galmed Pharmaceuticals

Genentech

General Automation Lab Technologies

Genetic Analysis

Genewiz

GenomeQuest

Georges Francois Leclerc Center

German Cryo

Hackensack Meridian Health

Hamilton Company

Harvard School of Public Health

Harvard University

Holobiome

Hospital of University of Strasbourg

Human Longevity

Hy Laboratories

IBM

Inserm

Institute For Life Science Entrepreneurship (ILSE)

Institut De Recherche Pour Le Developpement (IRD)

Institut Gustave Roussy

Institut National Recherche Agronomique

Intract Pharma

Intralytix

Ipsen

ISOThrive

Jackson Laboratory

Janssen Biotech

Janssen Human Microbiome Institute

Janssen Research & Development

Johnson & Johnson Consumer Companies

Johnson & Johnson Innovation

Johns Hopkins University

JSR

J Craig Venter Institute

Kaleido Biosciences

Karolinska Institute

Keio Gijuku University

Kenneth Rainin Foundation (KRF)

King's College Hospital

Kings College London

Lawrence Livermore National Laboratory

Leiden University

Leidos

Locus Biosciences

MaaT Pharma

Massachusetts General Hospital

Mayo Clinic

MD Anderson Cancer Center

Medical College of Wisconsin

Medical University of Graz

Memorial Sloan Kettering Cancer Center

MetaboGen

Metabolon

Metagenics

Metanome

Microbiotica

MilliporeSigma

Monsanto

MyBiotics Pharma

National Institutes of Health

National Institute of Allergy and Infectious Diseases

National Institute of Arthritis and Musculoskeletal Diseases

National Institute of Diabetes and Digestive and Kidney Diseases

National Psoriasis Foundation

Nestle Health Science

Norgen Biotek

North Zealand University Hospital

NuBiyota

NYU Langone Medical Center

Oncodesign

One Codex

OpenBiome

OpGen

OptiBiotix

OSEO

Owlstone Medical

Pathogenica

Pfizer

Pharmatest Services

Pierre Fabre

PureTech Health

Qiagen

Quark Venture

Rebiotix

Ritter Pharmaceuticals

Roswell Park Cancer Institute

Ruggles Family Foundation

SACCO

Salix Pharmaceuticals

Sanofi

SATT Lutech

Second Genome

Seres Therapeutics

Servier

Sirenas

Stanford Cancer Institute

Stanford University School of Medicine

Symbiotix Biotherapies

Synergie Lyon Cancer

Synlogic

Synthetic Biologics

Taconic Biosciences

Takeda Pharmaceutical

The BioCollective

The Parker Institute For Cancer Immunotherapy

Toulouse University Hospital

Transgene

UBiome

UCB

University College Cork

University College Hospital, Ibadan

University of Adelaide

University of Alberta

University of British Columbia

University of California, San Diego

University of California, San Diego (UCSD) School of Medicine

University of Cape Town

University of Chicago

University of Cincinnati

University of Heidelberg

University of Maryland

University of Maryland Institute for Genome Sciences (IGS)

University of Maryland Ventures

University of Nebraska

University of Pennsylvania

University of Rhode Island

University of South Alabama (USA) Mitchell Cancer Institute

University of Texas

University Pierre Marie Curie

Vedanta Biosciences

Vertex Pharmaceuticals

Washington University in St Louis

Weizmann Institute

Wellcome Trust

Western Connecticut Health Network

Xycrobe Therapeutics

Yeda Research and Development Company

Zymo Research

Microbiome deals by stage of development

Discovery

Preclinical

Phase I

Phase II

Phase III

Marketed

Microbiome deals by deal type

Asset purchase

Co-development

Collaborative R&D

Development

Distribution

Grant

Licensing

Manufacturing

Marketing

Option

Research

Sub-license

Supply

Termination

Microbiome deals by therapy area

Cardiovascular

Multiple sclerosis

Dental

Dermatology

Acne

Dermatitis

Eczema

Psoriasis

Gastrointestinal

Inflammatory bowel disease

Crohn's disease

Ulcerative colitis

Irritable bowel syndrome

Constipation

Diarrhea

Genetic disorders

Sickle cell disease

Gynaecology

Transplantation

Immunology

AIDS

Allergy

Graft versus host disease

Inflammation

Infectives

Bacterial

Clostridium difficile

Viral

HIV

Metabolic

Diabetes

Type 2

Liver disease

Nonalcoholic steatohepatitis (NASH)

Nutrition and vitamins

Pregnancy

Preterm labour

Oncology

Cervical cancer

Colorectal cancer

Bone metastases

Orphan disease

Pediatrics

Sleep disorders

Obesity

Respiratory

Asthma

Pneumonia

Wheeze

Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.